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DISCUSSION
Dr Thomas Huber (Gainesville, Fla). The authors have ana-
lyzed the outcome after carotid endarterectomy in both Maryland
and California over several years using administrative databases.
They reported that the overall stroke and mortality rates were less
than 1% in both states. The stroke rate decreased over the 10-year
time period of the study in Maryland, with race, calendar year, and
symptomatology associated with an increased incidence of stroke
by logistic regression. Not surprising, the stroke rates in Maryland
were inversely related to both hospital and provider specific vol-
umes. I have three questions/requests for the authors.
First, the utility of carotid endarterectomy represents a balance
between the risk of stroke associated with the procedure itself and
medical management. Although I would like to believe that stroke
risk associated with carotid endarterectomy is less than 1% in the
two states analyzed, I suspect that the actual rate is significantly
higher and that the incidence of stroke is under-reported in the
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respective databases. Indeed, the stroke rates for the prospective
carotid endarterectomy trials have consistently been higher and a
recent Cochrane Review of carotid endarterectomy for asymptomatic
stenoses, cited in the draft of the manuscript, reported a 2.9% periop-
erative stroke or death rate. I would appreciate your insight on the
accuracy of the perioperative stroke rate reported in your study.
Second, the incidence of carotid endarterectomies performed
for symptomatic lesions was only 15% in both states. This value is
significantly lower than traditionally reported and suggests that the
methodology for determining the symptomatic status of the ca-
rotid lesion is unreliable. Furthermore, the time course of the
symptoms relative to the carotid endarterectomy and their lateral-
ity are not completely clear. I would appreciate your insight on the
reliability of the carotid based symptoms.
Last and perhaps most important, how should these data be
interpreted given the expanding role of carotid angioplasty and
stent as an acceptable alternative to carotid endarterectomy for
extracranial carotid artery occlusive disease?
Dr Bauer Sumpio (New Haven, Conn). I just have two
questions. Very interesting presentation, but since you analyzed
two states, California and Maryland, I just wondered, as you did
the research, was there any difference in the way the data were
collected between the two states vis-à-vis payer mix. Since there is
a change or perhaps difference in payer mixes that occurred during
that 5- to 10-year period, I wonder if that could somehow affect
the way that the DRGs are reported and the data is accumulated.
My second question has to do with the fact that I believe Dr.
Kresowik from Iowa has done some analysis of five different states
as well within the Midwest looking at the differences in results
among five different Midwest states, and I wonder how your data
compares with the data that he has presented.
Dr W. Anthony Lee (Gainesville, Fla). I have a question and
kind of a basic comment. You know there are a lot of these
databases around and I was wondering why you chose to choose
those two states, Maryland simply because the origin of your
institution, but why California? Is there something specific about
that particular state you wanted to examine? Other studies have
come about fromNew York state and other populous states. When
I come across studies like this, which can be kind of broadly
described as observational studies, I always wonder what was your
initiating or a priori hypothesis if you will—maybe that is a bit of a
strong word, but events or ideas or provoking thoughts initiated a
study like this rather than just examining a database and seeing
what may kind of ultimately shake out, so I was wondering if you
could comment on that.
Dr James Elsey (Lawrenceville, Ga). I very much appreciated
your paper and it was a fine presentation. I do have one question.
The American College is struggling with the accuracy of coding,
but at the same time gathering an enormous amount of informa-
tion derived from coding. I know for a fact that in our hospital, our
coding is historically very inaccurate, though not necessarily driven
by a particular bias. Much of the data we gather to make decisions
is actually quite inaccurate–this becomes evident when we go back
and review the charts. Saying that, I wonder how accurate it is to
draw scientific and clinical conclusions from retrospective coding.
I would like that addressed. Thank you.
Dr Ali AbuRahma (Charleston, WV). I am just standing to
emphasize one of the comments by Dr Huber earlier about the
indication of surgery. It really worries me to quote a rate of only
15% symptomatic patients in this study. As everybody here knows,
carotid stenting is not approved by the government for asymptom-
atic lesions. The answer of cardiology colleagues and radiology,
say, well surgeons are doing it all the time. Guess what? I don’t
think we do it that way, because every respected article published
shows roughly at least 40% to 50% of indication for symptomatic
lesions, perhaps even more. To drop it to 15% is really worrisome,
so I am really wondering how the data were collected to differen-
tiate between symptomatic and asymptomatic, because that has a
great implication on how you practice carotid surgery.
Dr Susanna Matsen. Thank you for those questions. I would
like to start with Dr Huber’s questions regarding data collection.
This also touches on some of the other questions about the
potential for under-reporting in the database. We do agree that
within any sort of retrospective study such as this based off of
databases that there is of course the potential for under-reporting
of complications and deaths. We have a few ways that we have
addressed this.
For one, we used our own internal hospital database collected
by the division of vascular surgery in comparison with the Mary-
land hospital discharge databases, and these matched with no
significant coding inaccuracies identified.
Second, the methodology used in this report was the same as
previously used in two papers published by Dr Perler in theAnnals
of Surgery in 2000 and also JVS in 1998.We identified the carotids,
strokes, and symptomatic patients the same way. Both of those
papers quoted significantly higher stroke rates, so it seems clear
that surgical outcomes have improved over time.
Third, we have compared the Maryland data set with that from
California and found remarkably similar results. If indeed there were
gross under-reporting in the Maryland data set, this same gross
under-reporting would presumably have been present in the Califor-
nia database. In two states that are 3000 miles apart, the stroke rates
were remarkably similar.
Fourth, we did some unpublished analysis of the National
Inpatient Sample, which is a different data set that is designed to
represent all 50 states. It culls data from 37 states, and we analyzed
the stroke rates for all carotids in that data set in 2003 and found a
stroke rate of 0.4%.
Lastly, one would think that as medicine becomes more
crunched for finances that if anything, the reporting would err on
the side of over-reporting, as complications are associated with
higher billing.
The second question of Dr Huber regarded symptomatology
and whether or not the number of asymptomatic patients was so
much larger than the previous studies. I can say that the method-
ology again was the same, using those six different ICD-9 codes for
identifying carotid symptomatology. It was the same as the previ-
ous papers published by our group. Second, I think it is fair to say
that there is probably an increasing proportion of carotid endar-
terectomies that are being performed in Maryland on asymptom-
atic patients. And lastly, it could be that our methodology for
collecting this data in looking at those six ICD-9 codes for symp-
tomatology does not identify all symptomatic patients. Perhaps
some vascular surgeons are performing carotids on patients they
consider to be symptomatic but they do not end up being coded as
such. So I think it is difficult to draw too many conclusions except
that perhaps there is a decrease in the rate of symptomatic disease
patients being operated on in Maryland. Frankly, we believe that
the remarkably low rate of perioperative strokes identified in this
study and alluded to by the questioners may in fact relate to the
very high prevalence of CEAs being performed for asymptomatic
disease, where one would anticipate lower rates of perioperative
stroke.
The third question by Dr Huber had to do with carotid
angioplasty and stenting. We feel that based on the literature,
carotid stenting should play a role in the treatment of carotid
disease and it is probably most appropriate for high-risk patients.
We do feel that carotid endarterectomy remains the gold standard
for the majority of patients in contemporary practice at this time.
Regarding difference in the methodology of data collection in
the two states, both data sets were taken from parallel or mirroring
data sets. The Maryland data was taken from the Health Services
Cost Review Commission data set and the California data was
taken from the Office of Statewide Health Planning and Develop-
ment.
Regarding the work of Dr Kresowik, we have not specifically
analyzed his data in relation to the present study. In terms of why
we used California, it is true that there are many states that have
different data sets available for analysis. Previously our group has
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studied the New York State data as well as the Maryland data. We
chose California for diversity and also because the data set was
available to us.
The question addressing the hypothesis is an excellent one.
I think it is important to track the rate of these procedures that
we are performing in this country as well as outcomes. Since the
results of carotid angioplasty are apparently improving with
time, we were interested in examining whether such improve-
ment is also occurring with CEA in light of our previously
published studies. We also responded to stroke rates that were
being quoted in the literature for carotid artery stenting. Of
note, the stroke rate published within the SAPPHIRE trial for
CEAs was much higher than those published by vascular surgeons
in general.
Regarding the question about the ACS coding accuracy, I
again would refer to my previous answers about the fact that we had
validated this data to the best of our ability with our internal data with
the National Inpatient sample and with the California data.
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